Baird Medical Investment Azioni (NASDAQ: BDMD)

Ultime notizie per Baird Medical Investment (NASDAQ:BDMD) Azioni

Baird Medical Investment Holdings Ltd is one of the microwave ablation medical device developers and providers in the PRC for minimally invasive treatment of tumors. Its proprietary medical devices are used for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer and breast lumps. Microwave ablation is a minimally invasive treatment technique that denaturalizes and coagulates the protein of tumor cells with extreme heat generated by microwave energy. Microwave ablation treatments have been applied to benign and malignant tumors, and the company believes the products are safer, minimally invasive and easier to operate with faster recovery periods and lower complication rates for patients, as compared to traditional treatment methods.

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment Holdings Ltd

Baird Medical Investment Holdings Ltd - Warrant

Needham analyst Gerald Pascarelli reiterates Celsius Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) with a Buy and maintains $38 price target.

News

Price Target

Reiteration

Analyst Ratings

CELH

Needham Reiterates Buy on Celsius Holdings, Maintains $38 Price Target

Citigroup analyst Atif Malik upgrades Veeco Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VECO#NASDAQ">VECO</a>) from Neutral to Buy and announces $33 price target.

Upgrades

VECO

Citigroup Upgrades Veeco Instruments to Buy, Announces $33 Price Target

EYEN

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

Citigroup analyst Atif Malik upgrades FormFactor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORM#NASDAQ">FORM</a>) from Neutral to Buy and raises the price target from $44 to $51.

FORM

Citigroup Upgrades FormFactor to Buy, Raises Price Target to $51

Leerink Partners analyst Michael Cherny upgrades Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) from Market Perform to Outperform and raises the price target from $169 to $174.

Leerink Partners Upgrades Quest Diagnostics to Outperform, Raises Price Target to $174

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) with a Buy and maintains $26 price target.

ALMS

HC Wainwright & Co. Reiterates Buy on Alumis, Maintains $26 Price Target

AGIO

Agios Pharmaceuticals Filing Reported FDA Approved Update To PYRUKYND For Hemolytic Anemia In Adults With Pyruvate Kinase Deficiency; US Prescribing Info Revised To Include Liver Injury Risk

On Sunday, Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) backed OpenAI CEO Sam Altman disclosed that the company is currently operating at a loss on its $200 per month ChatGPT Pro plan.
Although the plan was designed to generate revenue, it is not producing the profits OpenAI had anticipated. Altman shared his thoughts on the issue through a <a target="_blank" href="https://x.com/sama" rel="noreferrer noopener">series of posts on X</a>, stating that the price was set under the assumption that it would help the company earn revenue, but usage has exceeded their expectations.
"we are currently losing money on openai pro subscriptions! people use it much more than we expected," he said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">insane thing: we are currently losing money on openai pro subscriptions! people use it much more than we expected.
&mdash; Sam Altman (@sama) <a href="https://twitter.com/sama/status/1876104315296968813?ref_src=twsrc%5Etfw">January 6, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
OpenAI launched ChatGPT Pro late last year to offer its users an upgraded experience. The new plan offers unlimited access to all of OpenAI's models, including the <a target="_blank" href="https://www.benzinga.com/tech/24/12/42356469/openai-unveils-200-chatgpt-pro-subscription-inside-the-o1-reasoning-model-and-what-it-means-for-power-users" rel="noreferrer noopener">advanced "o1" reasoning model</a>.
Internal testing showed a 34% reduction in major errors on difficult questions compared to the preview version.&nbsp;
Despite the promising features, OpenAI has yet to reach profitability despite raising $20 billion since its inception, <a target="_blank" href="https://techcrunch.com/2025/01/05/openai-is-losing-money-on-its-pricey-chatgpt-pro-plan-ceo-sam-altman-says/" rel="noreferrer noopener">TechCrunch</a> reported. In October, the company secured more than $6.5 billion in new funding at a<a target="_blank" href="https://www.benzinga.com/news/24/10/41149788/openai-valuation-soars-to-157b-in-latest-funding-round" rel="noreferrer noopener"> valuation of $157 billion</a>.
The latest funding is said to be one of the largest private investments ever alongside&nbsp;SpaceX and TikTok parent&nbsp;ByteDance.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42782683/tesla-hits-record-ev-sales-in-china-despite-global-dip" rel="noreferrer noopener">Tesla Hits Record EV Sales In China Despite Global Dip: Report</a>
It is to be noted that the company plans to transition from being controlled by a nonprofit board to a new structure, paving the way for an <a target="_blank" href="https://www.benzinga.com/news/24/09/41043358/sam-altman-poised-for-10-5b-payday-as-openai-transitions-to-for-profit-model-with-150b-valuation-on" rel="noreferrer noopener">initial public offering (IPO) in the future</a>.
However, Billionaire&nbsp;and OpenAI co-founder&nbsp;Elon Musk has filed for an injunction&nbsp;to halt the transition, accusing OpenAI of <a target="_blank" href="https://www.benzinga.com/24/12/42712683/openai-lays-out-its-for-profit-transition-plans-says-it-must-evolve-to-advance-its-agi-mission" rel="noreferrer noopener">deviating from its original mission</a>.
In 2023, the company projected losses of about $5 billion on $3.7 billion in revenue. High operating expenses, including costs of approximately $700,000 per day to support the ChatGPT platform, are contributing to its financial struggles.
To counter these losses, OpenAI is exploring strategies to become profitable. One potential solution involves increasing the price of its subscription tiers.
In December, OpenAI said it is planning to reach 1 billion users by 2025, driven by new AI products, <a target="_blank" href="https://www.benzinga.com/media/24/12/42259023/apple-partnership-ai-agents-and-major-infrastructure-investments-openai-executives-outline-strategy-to-attract-1b-users-by-2025" rel="noreferrer noopener">infrastructure and partnership</a> with&nbsp;Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>).
Also, Sam Altman shared his thoughts in a blog post regarding the company's ongoing efforts to build artificial general intelligence (AGI) and its <a target="_blank" href="https://blog.samaltman.com/reflections" rel="noreferrer noopener">eventual goal of superintelligence</a>.
"With superintelligence, we can do anything else. Superintelligent tools could massively accelerate scientific discovery and innovation well beyond what we are capable of doing on our own, and in turn massively increase abundance and prosperity."
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/42787508/biden-blocks-14-9b-us-steel-takeover-shares-plunge" target="_blank" rel="noreferrer noopener">Biden Blocks $14.9B US Steel Takeover</a></li>
</ul>
Photo via Shutterstock

Tech

Media

AAPL

MSFT

OpenAI CEO Sam Altman Says Company Losing Money On ChatGPT Pro Plan

Citigroup analyst Atif Malik upgrades Advanced Energy Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEIS#NASDAQ">AEIS</a>) from Neutral to Buy and raises the price target from $110 to $138.

AEIS

Citigroup Upgrades Advanced Energy Indus to Buy, Raises Price Target to $138

Guidance

Commercial Metals Expects Q2 Fiscal 2025 Consolidated Financial Results To Decline From The Q1 Fiscal 2025 Level

Commercial Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMC#NYSE">CMC</a>) reported quarterly earnings of $0.78 per share which missed the analyst consensus estimate of $0.81 by 3.7 percent. The company reported quarterly sales of $1.910 billion which beat the analyst consensus estimate of $1.873 billion by 1.96 percent. This is a 4.66 percent decrease over sales of $2.003 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

Commercial Metals Q1 2025 Adj. EPS $0.78 Misses $0.81 Estimate, Sales $1.910B Beat $1.873B Estimate

B of A Securities analyst Michael Cherny upgrades Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from Neutral to Buy and raises the price target from $132 to $145.

B of A Securities Upgrades Cardinal Health to Buy, Raises Price Target to $145

Citigroup analyst Atif Malik upgrades Nova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVMI#NASDAQ">NVMI</a>) from Neutral to Buy and raises the price target from $226 to $240.

NVMI

Citigroup Upgrades Nova to Buy, Raises Price Target to $240

U.S. stocks settled higher on Friday, with the S&amp;P 500 and Nasdaq Composite snapping a five-day losing streak.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Jay McCanless
<ul>
<li>Analyst Firm: Wedbush</li>
<li>Ratings Accuracy: 87%</li>
<li>Latest Rating: Upgraded rating on PulteGroup, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>) from Neutral to Outperform with a price target of $135 on Jan. 3. This analyst sees around 23% upside in the stock.</li>
<li>Recent News: PulteGroup will release its fourth quarter 2024 financial results before the market opens on Thursday, Jan. 30.</li>
</ul>
Analyst: Chris Kotowski
<ul>
<li>Analyst Firm: Oppenheimer</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained an Outperform rating on Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) and cut the price target from $110 to $102 on Jan. 3. This analyst sees around 41% upside in the stock.</li>
<li>Recent News: On Dec. 10, Citigroup CFO said that bank will be at high end of guidance for 2024.</li>
</ul>
Analyst: William Stein 
<ul>
<li>Analyst Firm: Truist Securities</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained a Hold rating on Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and cut the price target from $360 to $351 on Jan. 3. This analyst sees around 16% downside in the stock.</li>
<li>Recent News: The EV maker reported approximately 83,000 units sold in China during December, a 12.8% increase compared to November, according to a report from CnEV Post.</li>
</ul>
Analyst: Mark Palmer
<ul>
<li>Analyst Firm: Benchmark</li>
<li>Ratings Accuracy: 83%</li>
<li>Latest Rating: Reiterated a Buy rating on Dave Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) with a price target of $119 on Jan. 2. This analyst sees around 32% surge in the stock.</li>
<li>Recent News: On Dec. 30, the Department of Justice (DOJ) and the Federal Trade Commission (FTC) filed a civil enforcement action against financial technology company Dave and its CEO, Jason Wilk, alleging violations of consumer protection laws..</li>
</ul>
Analyst: Trey Grooms
<ul>
<li>Analyst Firm: Stephens &amp; Co.</li>
<li>Ratings Accuracy: 82%</li>
<li>Latest Rating: Reiterated an Overweight rating on Vulcan Materials Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>) with a price target of $325 on Jan. 2. This analyst sees around 26% upside in the stock.</li>
<li>Recent News: On Dec. 11, Vulcan Materials entered into a definitive agreement to acquire Superior Ready Mix Concrete, L.P. for an undisclosed amount.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42791037/delta-air-lines-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Delta Air Lines Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

DAVE

TSLA

This Analyst With 85% Accuracy Rate Sees Around 16% Downside In Tesla - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts

HC Wainwright &amp; Co. analyst Robert Burns reiterates Nuvation Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>) with a Buy and maintains $7 price target.

NUVB

HC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $7 Price Target

B of A Securities analyst Michael Cherny upgrades Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) from Underperform to Buy and raises the price target from $69 to $84.

HSIC

B of A Securities Upgrades Henry Schein to Buy, Raises Price Target to $84

B of A Securities analyst Geoff Meacham maintains Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) with a Buy and lowers the price target from $22 to $7.

NMRA

B of A Securities Maintains Buy on Neumora Therapeutics, Lowers Price Target to $7

BTC Held: 1,720 BTC1 as of December 31, 2024.

FUFU

BitFuFu Says It Produced 111 Bitcoins In December 2024 From Self-mining Operations, 32% Increase From November - Filing

Citigroup analyst Christopher Allen downgrades CME Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) from Buy to Neutral and lowers the price target from $255 to $250.

Downgrades

Citigroup Downgrades CME Gr to Neutral, Lowers Price Target to $250

Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) with a Buy and maintains $6 price target.

TSHA

Needham Reiterates Buy on Taysha Gene Therapies, Maintains $6 Price Target

Baird Q3 2024 Mid Cap Growth Equity Fund Commentary

10:24 EST Baird Medical (BDMD) Investment Holdings Ltd trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

Baird Medical Investment Holdings Ltd trading resumes

10:19 EST Baird Medical (BDMD) Investment Holdings Ltd trading halted, volatility trading pause Published first on TheFly – the ultimate source for...

Comments

Baird Medical Investment

Notizie

Ultime notizie per Baird Medical Investment (NASDAQ:BDMD) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO